Vertex completes Phase 4 study of suzetrigine for opioid use after knee replacement
Vertex Pharmaceuticals has completed a Phase 4 trial examining opioid use in patients given suzetrigine after total knee arthroplasty.
Vertex Pharmaceuticals closed out a Phase 4 study this week on pain treatment following knee replacement surgery.
- "A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty" (NCT07538570) is listed as completed, with a study that aims to characterize opioid use after total knee arthroplasty (TKA)1. The trial enrolled 66 participants, with a non randomized allocation and a sequential intervention model1, comparing suzetrigine (also known as VX-548 or JOURNAVX) against placebo, each given for 14 days1. The primary outcome was total opioid usage measured from 24 hours to 168 hours after the first dose of study drug1. Primary completion was listed as 2026-10-12 and study completion as 2026-10-22, both actual dates, per the registry record.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.